ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.
Tumour Sites: Gynaecological Malignancies
Latest ESMO videos
Featured medwireNews
PARP Inhibitor-Based Triplet Regimen ‘Feasible’ For Advanced Endometrial Carcinoma
Lenvatinib–Pembrolizumab Boost Advanced Endometrial Cancer Survival
DESKTOP III: Cytoreductive Surgery Extends Recurrent Ovarian Cancer Survival
SOLO1 Update Confirms Long-Term PFS Benefit Of Olaparib Maintenance
OUTBACK Trial: No Cervical Cancer Survival Gain With Adjuvant Chemotherapy
E-Learning
Factsheets on Biomarkers
BRCA1 and BRCA2 in Ovarian Cancer: ESMO Biomarker Factsheet
Meeting resources
Immunotherapy plus PARP
Presenter: Anniina Färkkilä
Session: Gynaecological malignancies and breast tumours
Resources:
Slides
Webcast
Antibody responses in the TME
Presenter: Ziv Shulman
Session: B cells as a therapeutic opportunity
Resources:
Slides
Webcast
T cells in clinical immunotherapy for gynaecological cancers
Presenter: Dmitriy Zamarin
Session: Predictive factors for T cell therapy
Resources:
Slides
Webcast
176O - Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Presenter: Shoji Nagao
Session: Proffered Paper session: Gynaecological tumours
Resources:
Abstract
Slides
Webcast
178O - Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENA–MONO study
Presenter: Keiichi Fujiwara
Session: Proffered Paper session: Gynaecological tumours
Resources:
Abstract
Slides
Webcast